Angie Drakulich

Our editorial advisory board members provide their perspective on what's ahead in the biopharmaceutical industry.

FDA talks about the changing scope of regulatory science.

A recent ISPE guidance provides a baseline for the design of quality laboratory facilities.

Keeping tabs on crucial medicines should be part of consumers' and manufacturers' emergency-preparedness plans.

Global coordination tactics that incorporate online technologies and social media are reshaping disease prevention and response.

NECC gets 483 after fungal meningitis outbreak.

At this week's AAPS 2012 Annual Meeting in Chicago, graduate students across the country are being honored for their research and work in bio/pharmaceutical innovation. BioPharm International had the chance to talk with a few of the recipients.

Will the next US President support the backbone of our industry?

Although FDA cannot do anything to stop drugs from being discontinued, it can do something about supply and quality problems that lead to shortages.